<SEC-DOCUMENT>0001193125-26-258366.txt : 20260605
<SEC-HEADER>0001193125-26-258366.hdr.sgml : 20260605
<ACCEPTANCE-DATETIME>20260605070517
ACCESSION NUMBER:		0001193125-26-258366
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20260602
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260605
DATE AS OF CHANGE:		20260605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Seres Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001609809
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				274326290
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37465
		FILM NUMBER:		261066848

	BUSINESS ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617 945 9626

	MAIL ADDRESS:	
		STREET 1:		200 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Seres Health, Inc.
		DATE OF NAME CHANGE:	20140603
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d156701d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mcrb="http://serestherapeutics.com/20260602" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-314">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2026-06-02_to_2026-06-02">0001609809</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="mcrb-20260602.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2026-06-02_to_2026-06-02"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001609809</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2026-06-02</xbrli:startDate> <xbrli:endDate>2026-06-02</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-325">8-K</ix:nonNumeric></span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2026-06-02_to_2026-06-02" format="ixt:datemonthdayyearen" id="ixv-326">June 2, 2026</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-327">SERES THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2026-06-02_to_2026-06-02" format="ixt-sec:stateprovnameen" id="ixv-328">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-329">001-37465</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-330">27-4326290</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-331">101 Cambridgepark Drive</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-332">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-333">MA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-334">02140</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-335">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-336">945-9626</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2026-06-02_to_2026-06-02" format="ixt-sec:boolballotbox" id="ixv-337">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2026-06-02_to_2026-06-02" format="ixt-sec:boolballotbox" id="ixv-338">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2026-06-02_to_2026-06-02" format="ixt-sec:boolballotbox" id="ixv-339">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2026-06-02_to_2026-06-02" format="ixt-sec:boolballotbox" id="ixv-340">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-341">Common stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-342">MCRB</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2026-06-02_to_2026-06-02" format="ixt-sec:exchnameen" id="ixv-343">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2026-06-02_to_2026-06-02" format="ixt-sec:boolballotbox" id="ixv-344">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of Asset Purchase Agreement</span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;2, 2026, Seres Therapeutics, Inc. (the &#8220;Company&#8221;) entered into Amendment No.&#160;1 (the &#8220;APA Amendment&#8221;) to the Asset Purchase Agreement, dated as of August&#160;5, 2024 (as previously amended by that certain Letter Agreement, dated September&#160;30, 2024 and that certain Letter Agreement, dated December&#160;31, 2024, the &#8220;Purchase Agreement&#8221;), by and between the Company and Soci&#233;t&#233; des Produits Nestl&#233; S.A., a soci&#233;t&#233; anonyme organized under the laws of Switzerland (&#8220;SPN&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Purchase Agreement, SPN agreed to pay the Company certain <span style="white-space:nowrap">one-time</span> contingent milestone payments during the Milestone Period (as defined in the Purchase Agreement) if and following the first time that the worldwide annual net sales of the Product (as defined in the Purchase Agreement) reached the following thresholds: (i)&#160;a $125.0&#160;million milestone payment upon the first calendar year in which annual worldwide net sales of the Product equal or exceed $400.0&#160;million (the &#8220;Second Sales Milestone Payment&#8221;); and (ii)&#160;a $150.0&#160;million milestone payment upon the first calendar year in which annual worldwide net sales of the Product equal or exceed $750.0&#160;million (the &#8220;Third Sales Milestone Payment&#8221;). Pursuant to the Purchase Agreement, the Prepaid Milestone (as defined in the Purchase Agreement) accrued interest during the Milestone Period (as defined in the Purchase Agreement), which would reduce the Second Milestone Payment to Seres if and when it became payable (the &#8220;Milestone Interest Payments&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the APA Amendment, the parties agreed to terminate SPN&#8217;s obligations with respect to the Second Sales Milestone Payment, the Third Sales Milestone Payment and eliminate the Milestone Interest Payments that would have been due from the Company to SPN. In consideration for the foregoing, SPN agreed to a <span style="white-space:nowrap">one-time</span> payment to the Company of $25.0&#160;million (the &#8220;Milestone Termination Payment&#8221;), which amount is payable in two equal installments of $12.5&#160;million, with the first installment payable on July&#160;1, 2026 and the second installment payable on October&#160;1, 2026. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the APA Amendment does not purport to be complete and is qualified in its entirety by reference to the APA Amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of Lease </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;4, 2026, the Company entered into the First Amendment to Lease (the &#8220;Lease Amendment&#8221;) with 101 CPD LLC (f/k/a HCP/King 101 CPD LLC), a Delaware limited liability company (the &#8220;Landlord&#8221;), which amends the Lease Agreement, dated September&#160;22, 2021, by and between the Company and the Landlord (as amended, the &#8220;Lease&#8221;), pursuant to which the Company leases approximately 82,714 rentable square feet of office and laboratory space located at 101 CambridgePark Drive, Cambridge, Massachusetts (the &#8220;Existing Premises&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lease Amendment provides for (i)&#160;effective as of April&#160;30, 2026, the surrender by the Company to the Landlord of an aggregate area of approximately 45,832 rentable square feet of the Existing Premises (the &#8220;Early Termination Premises&#8221;), (ii) the revision of the expiration date of the term of the Lease with respect to the remaining 36,882 rentable square feet of the Existing Premises (the &#8220;Renewal Premises&#8221;) from March&#160;31, 2033 to December&#160;31, 2036, (iii) effective as of May&#160;1, 2026, the reduction of the base rent the Company is obligated to pay the Landlord for the Renewal Premises to $79.70 per rentable square foot of the Renewal Premises per year, subject to an annual adjustment, resulting in an aggregate decrease of approximately $33.9&#160;million in lease payments, (iv)&#160;a deferral of rent payments due monthly for the eight months from May&#160;1, 2026 through December&#160;31, 2026 to a lump sum payment due on January&#160;4, 2027, and (v)&#160;a decrease in the Company&#8217;s share of operating costs and taxes for the building from 51.36% to 24.25% consistent with the decrease in square footage. As consideration for the Lease Amendment, the Company agreed to pay the following: (i)&#160;a $4.5&#160;million termination fee for the Early Termination Premises payable on the execution of the Lease Amendment, and (ii)&#160;on or before January&#160;4, 2027, a deferred payment of $5.2&#160;million which may be issued either as an unconditional letter of credit or in cash, of which $2.0&#160;million will satisfy Company&#8217;s rent obligations for the period from May&#160;1, 2026 through December&#160;31, 2026 and $3.2&#160;million representing an additional termination payment. Further, the Company permitted the Landlord to draw the existing letter of credit (&#8220;Existing Letter of Credit&#8221;) held by Landlord under the Lease equal to $6.3&#160;million. The Existing Letter of Credit is recorded as restricted cash on the Company&#8217;s balance sheets and, accordingly, is not considered in the Company&#8217;s cash runway projections. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Lease Amendment does not purport to be complete and is qualified in its entirety by reference to the Lease Amendment, a copy of which is attached as Exhibit 10.2 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;5, 2026, the Company issued a press release regarding the APA Amendment and the Lease Amendment, a copy of which is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d156701dex101.htm">Amendment No.&#160;1 to Asset Purchase Agreement, dated June&#160;2, 2026, by and between Seres Therapeutics, Inc. and Soci&#233;t&#233; des Produits Nestl&#233; S.A. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d156701dex102.htm">First Amendment to Lease, dated June&#160;4, 2026, by and between Seres Therapeutics, Inc. and 101 CPD, LLC </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d156701dex991.htm">Press Release, dated June&#160;5, 2026 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of <span style="white-space:nowrap">Regulation&#160;S-K.&#160;The</span> Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission. </p></td></tr></table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">SERES THERAPEUTICS, INC.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: June&#160;5, 2026</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas J. DesRosier</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Thomas J. DesRosier</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and Chief Legal Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d156701dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 1 TO THE ASSET PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Amendment No.&nbsp;1 (this &#8220;<U>Amendment</U>&#8221;) to the Asset Purchase Agreement, dated as of August 5, 2024 (as amended by
that certain Letter Agreement, dated September 30, 2024 and that certain Letter Agreement, dated December&nbsp;31, 2024, the &#8220;<U>Agreement</U>&#8221;), by and between SERES THERAPEUTICS, INC., a corporation organized and existing under the
laws of Delaware (&#8220;<U>Seller</U>&#8221;) and SOCI&Eacute;T&Eacute; DES PRODUITS NESTL&Eacute; S.A., a <I>soci&eacute;t&eacute; anonyme </I>organized under the laws of Switzerland (&#8220;<U>Purchaser</U>&#8221; and together with Seller each a
&#8220;<U>Party</U>&#8221; and collectively the &#8220;<U>Parties</U>&#8221;), is made and entered into as of May&nbsp;28, 2026 by and among the Parties. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned
to such terms in the Agreement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Purchaser and Seller are parties to the Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to the Agreement, Seller sold, conveyed, assigned, transferred and delivered to Purchaser, and Purchaser purchased and
accepted, the Acquired Assets, subject to the terms and conditions set forth therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;3.4(a) of the
Agreement, Purchaser agreed to pay to Seller, during the Milestone Period, certain <FONT STYLE="white-space:nowrap">one-time</FONT> contingent Milestone Payments following the first time that the Net Sales of Product in the entire world reach
specified thresholds, including a </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">$125,000,000 Milestone Payment upon the first Calendar Year in which annual Net Sales of Product in the entire world
equal or exceed $400,000,000 (such payment, the &#8220;<U>Second Sales</U> <U>Milestone Payment</U>&#8221;) and a $150,000,000 Milestone Payment upon the first Calendar Year in which annual Net Sales of Product in the entire world equal or exceed
$750,000,000 (such payment, the &#8220;<U>Third Sales Milestone Payment</U>&#8221;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, pursuant to Section&nbsp;3.3 of the
Agreement: the Prepaid Milestone accrues interest at a fixed rate of (a) 10.0% per annum (compounding annually) from, and including, the Closing Date through, but excluding, the date of achievement of the First Sales Milestone and (b) 5.0% per annum
(compounding annually) from, and including, the date of achievement of the First Sales Milestone through, but excluding, the earlier of (i)&nbsp;the date on which the Prepaid Milestone, together with accrued interest thereon, has been repaid in full
by <FONT STYLE="white-space:nowrap">set-off</FONT> under Section&nbsp;3.4; and (ii)&nbsp;the last day of the Milestone Period, and the Prepaid Milestone, together with accrued interest thereon, is to be settled only through a reduction of any
Milestone Payments that become payable under Section&nbsp;3.4 and, if any amount of the Prepaid Milestone (and any accrued interest thereon) remains outstanding as of following the last day of the Milestone Period, the balance thereof (together with
any interest accrued thereon) shall be forgiven and the right of <FONT STYLE="white-space:nowrap">set-off</FONT> of Purchaser with respect thereto shall be deemed forfeited (such interest payments that remain accruable and payable, the
&#8220;<U>Milestone Interest Payments</U>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties desire to terminate Purchaser&#8217;s obligations with respect to
the Second Sales Milestone Payment, the Third Sales Milestone Payment and the Milestone Interest Payments under the Agreement in consideration of a termination payment by Purchaser in accordance with the terms hereof; and </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing and the covenants and agreements contained
herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, each of the Parties, intending to be legally bound, hereby agrees as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.
<U>Milestone Payment Acknowledgment</U>. The Parties acknowledge and agree that at Closing, Purchaser paid the Prepaid Milestone to Seller in accordance with Section&nbsp;3.1(a) of the Agreement and satisfied its Milestone Payment for the First
Sales Milestone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Milestone Termination Payment.</U> In consideration of the termination of Purchaser&#8217;s obligations with
respect to the Second Sales Milestone Payment, the Third Sales Milestone Payment and the Milestone Interest Payments under the Agreement, Purchaser shall pay to Seller a <FONT STYLE="white-space:nowrap">one-time</FONT> payment in the aggregate
amount of Twenty-Five Million US Dollars ($25,000,000) in full satisfaction, termination and discharge of the Second Milestone Payment and the Third Milestone Payment (such payment, the &#8220;<U>Milestone Termination Payment</U>&#8221;). The
Milestone Termination Payment shall be payable in two equal installments, with the first installment of Twelve Million Five Hundred Thousand U.S. Dollars ($12,500,000) payable on July 1, 2026 and the second installment of Twelve Million Five Hundred
Thousand US Dollars ($12,500,000) payable on October 1, 2026. Each installment of the Milestone Termination Payment shall be paid in accordance with Section&nbsp;3.7 of the Agreement. For all purposes of the Agreement and the definition of
&#8220;Purchase Price,&#8221; the Milestone Termination Payment shall constitute a &#8220;Milestone Payment&#8221; as defined under the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of Seller</U>. Seller represents and warrants to Purchaser as of the date hereof: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Authority; Binding Effect</U>. Seller has the requisite corporate power and authority to execute and deliver
this Amendment and to perform its obligations hereunder. The execution and delivery of this Amendment by Seller and the performance by Seller of its obligations hereunder have been duly authorized by all necessary corporate action on the part of
Seller. This Amendment has been duly executed and delivered by Seller and constitutes a valid and binding obligation of Seller, enforceable against Seller in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium or similar Laws of general application affecting or relating to the enforcement of creditors&#8217; rights generally and subject to equitable principles of general applicability. The Board has unanimously
(x)&nbsp;determined that this Amendment and the transactions contemplated herein, including the Milestone Termination Payment, are fair to and in the best interests of Seller and its stockholders and declared it advisable to enter into this
Amendment with Purchaser; and (y)&nbsp;adopted resolutions approving this Amendment and the transactions contemplated hereby, including the Milestone Termination Payment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Solvency</U>. Seller is Solvent as of the date hereof and, after giving effect to this Amendment, including
the amendment, termination, cancellation, elimination and waiver of rights contemplated hereby, will be Solvent. Seller will not be rendered insolvent as a result of the transaction contemplated herein and Seller is not currently engaged in, nor
about to engage in, any business or transaction for which the property remaining with Seller constitutes unreasonably small capital. For purposes of this Amendment, &#8220;<U>Solvent</U>&#8221; means that, as of the relevant time of determination,
(a)&nbsp;the fair value and present fair saleable value of Seller&#8217;s assets exceed Seller&#8217;s debts and liabilities, subordinated, contingent or otherwise, (b)&nbsp;Seller is able to pay its debts and liabilities, subordinated, contingent
or otherwise, as they become absolute and mature, and (c)&nbsp;Seller does not have unreasonably small capital with which to conduct the business in which it is engaged or proposed to be engaged. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Fair Value; Reasonably Equivalent Value</U>. Seller has independently evaluated the value of the rights
being amended, terminated, cancelled, eliminated and waived pursuant to this Amendment, including the contingent nature, uncertainty, timing, probability and risks associated with the Second Milestone Payment and the Third Milestone Payment. Seller
acknowledges and agrees that the Milestone Termination Payment constitutes fair value, fair consideration and reasonably equivalent value for the rights being amended, terminated, cancelled, eliminated and waived pursuant to this Amendment. Seller
further acknowledges and agrees that this Amendment was negotiated at arms&#8217; length between Seller and Purchaser, and that the Milestone Termination Payment was determined based on good faith negotiations between the Parties.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Intent to Hinder, Delay or Defraud</U>. Seller is not entering into this Amendment, or consummating the
transactions contemplated hereby, with any intent to hinder, delay or defraud any present or future creditor of Seller. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Representations and Warranties of Purchaser</U>. Purchaser represents and warrants to Purchaser as of the date hereof: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Authority; Binding Effect</U>. Purchaser has the requisite corporate power and authority to execute and
deliver this Amendment and to perform its obligations hereunder. The execution and delivery of this Amendment by Purchaser and the performance by Purchaser of its obligations hereunder have been duly authorized by all necessary corporate action on
the part of Purchaser. This Amendment has been duly executed and delivered by Purchaser and constitutes a valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium or similar Laws of general application affecting or relating to the enforcement of creditors&#8217; rights generally and subject to equitable principles of general applicability. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Effect of Amendment</U>. Except as expressly provided in Section&nbsp;1 through
Section&nbsp;4 herein, and in such case, subject to the terms and conditions set forth therein, this Amendment shall not constitute an amendment, modification or waiver of any provision of the Agreement or any rights, remedies or obligations of any
party under or in respect of the Agreement. Except as expressly modified by Section&nbsp;1 and Section&nbsp;2 herein of this Amendment, the Agreement shall continue in full force and effect. Upon the execution of this Amendment by each of Purchaser
and Seller, each reference in the Agreement to &#8220;this Agreement&#8221; or the words &#8220;hereunder,&#8221; &#8220;hereof,&#8221; &#8220;herein&#8221; or words of similar effect referring to the Agreement shall mean and be a reference to the
Agreement as amended by this Amendment, and a reference to the Agreement in any other instrument or document shall be deemed a reference to the Agreement as amended by this Amendment. This Amendment shall be subject to, shall form a part of, and
shall be governed by, the terms and conditions set forth in the Agreement, as amended by this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>General</U>. Article 10 of
the Agreement shall apply, and is hereby incorporated herein by reference, to this Amendment <I>mutatis mutandis</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed on their
behalf as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SERES THERAPEUTICS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Richard Kender</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Richard Kender</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Executive Chairman and Interim CEO</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SOCI&Eacute;T&Eacute; DES PRODUITS NESTL&Eacute; S.A.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">/s/ Claudio Kuoni</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Claudio Kuoni</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Vice President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d156701dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FIRST AMENDMENT TO LEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This FIRST AMENDMENT TO LEASE (this &#8220;<B>Amendment</B>&#8221;) is entered into as of May&nbsp;1, 2026 (the &#8220;<B>Effective
Date</B>&#8221;), by and between 101 CPD LLC, a Delaware limited liability company (&#8220;<B>Landlord</B>&#8221;), and SERES THERAPEUTICS, INC., a Delaware corporation (&#8220;<B>Tenant</B>&#8221;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>R E C I T A L S</U>: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.
Landlord&#8217;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">predecessor-in-interest,</FONT></FONT> HCP/King 101 CPD LLC, as original landlord, and Tenant entered into that certain Lease dated as of September&nbsp;22, 2021 (the
&#8220;<B>Lease</B>&#8221;) pursuant to which Landlord currently leases to Tenant, and Tenant currently leases from Landlord, that certain space (collectively, the &#8220;<B>Premises</B>&#8221;) comprising (i) 8,951 rentable square feet on the first
(1st) floor (including the Storage Premises, as defined in the Lease) (the &#8220;<B>First Floor Premises</B>&#8221;), (ii) 35,575 rentable square feet on the fourth (4th) floor (the &#8220;<B>Fourth Floor Premises</B>&#8221;), (iii) 35,575 rentable
square feet on the fifth (5th) floor (the &#8220;<B>Fifth Floor Premises</B>&#8221;), and (iv) 2,614 rentable square feet on the Penthouse floor, containing 82,714 rentable square feet in the aggregate, in that certain five-story building containing
approximately 161,040 rentable square feet and located at 101 CambridgePark Drive, Cambridge, MA 02140 (the &#8220;<B>Building</B>&#8221;) for a term that is scheduled to expire on March&nbsp;31, 2033. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Tenant and Landlord desire to enter into this Amendment in order to (i)&nbsp;terminate the Lease with respect to the First Floor Premises,
the Fifth Floor Premises, and a portion of the Penthouse floor premises equal to 1,307 rentable square feet (collectively, the &#8220;<B>Early Termination Premises</B>&#8221;) as of April&nbsp;30, 2026 (the &#8220;<B>Early</B> <B>Termination
Date</B>&#8221;), (ii)&nbsp;extend the Term of the Lease with respect to the Fourth Floor Premises and a portion of the Penthouse floor premises equal to 1,307 rentable square feet, such that after the Effective Date, the Remainder Premises shall
equal 36,882 rentable square feet (the &#8220;<B>Remainder Premises</B>&#8221;), and (iii)&nbsp;to otherwise modify certain terms and conditions of the Lease in connection therewith, all as otherwise provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, Landlord and
Tenant agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><U>Recitals; Capitalized Terms</U></B>. All of the foregoing recitals are true and correct. Unless
otherwise defined herein, all capitalized terms used in this Amendment shall have the meanings ascribed to them in the Lease, and all references herein or in the Lease to the &#8220;Lease&#8221; or &#8220;this Lease&#8221; or &#8220;herein&#8221; or
&#8220;hereunder&#8221; or similar terms or to any section thereof shall mean the Lease, or such section thereof, as amended by this Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><U>Early Termination; Termination Fee; Letters of Credit</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. The Term of the Lease with respect to the Early Termination Premises only shall terminate on the Early Termination Date.
Tenant&#8217;s furniture, fixtures, and equipment in the Early Termination Premises shall be transferred and conveyed to Landlord as of the Early Termination Date pursuant to a bill of sale in the form attached hereto and made a part hereof as
<U>Exhibit A</U> to be executed and delivered by Tenant to Landlord concurrently with the execution of this Amendment. Tenant shall have no further obligations or liabilities with respect to the Early Termination Premises pursuant to the original
Lease </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
only, including without limitation, obligations under the original Lease relating to rent, operating expenses, taxes, utilities, maintenance, repairs, insurance, indemnification, cleaning,
parking, and hazardous materials compliance, except for those obligations and responsibilities that survive under the original Lease. Tenant and Landlord each hereby acknowledge and agree that decommissioning obligations required to be performed by
Tenant under the Lease with respect to the Early Termination Premises have been fully satisfied and completed as of the Early Termination Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. As consideration for Landlord to enter into this Amendment and to terminate the Lease with respect to the Early Termination
Premises, Tenant shall pay to Landlord a sum equal to $4,500,000.00 (the &#8220;<B>Early Termination Fee</B>&#8221;) simultaneously with Tenant&#8217;s execution and delivery of this Amendment to Landlord. The parties acknowledge that Tenant shall
receive a <FONT STYLE="white-space:nowrap">one-time</FONT> credit in the amount of $931,627 for prepaid Base Rent and Operating Expenses and Taxes by Tenant for the month of May, 2026 for the Early Termination Premises and the Remainder Premises,
such that the net amount payable by Tenant upon execution of this Amendment is $3,568,373. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. As further consideration for
Landlord to enter into this Amendment, Tenant agrees that at any time after the Effective Date, Landlord may draw the full amount of the existing Letter of Credit (&#8220;<B>Existing Letter of Credit</B>&#8221;) held by Landlord under the Lease
equal to $6,265,585.53 and retain the proceeds thereof. Tenant agrees to execute any additional documentation as reasonably required by Landlord in connection with Landlord&#8217;s draw of the Existing Letter of Credit. In connection therewith, the
parties acknowledge and agree that Tenant hereby forever relinquishes and releases all of its right, title and interest in and to the proceeds of the Existing Letter of Credit so drawn and agrees that Landlord shall have no obligation to return any
amounts thereof to Tenant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. On or before January&nbsp;4, 2027, Tenant shall cause a new Letter of Credit (the
&#8220;<B>New Letter of Credit</B>&#8221;) to be issued to Landlord in the amount of $1,470,000 by JPMorgan Chase Bank in the form attached hereto as Exhibit B and satisfying the conditions of Section&nbsp;7.1 of the original Lease. Such New Letter
of Credit shall be held by Landlord in accordance with and subject to the terms and conditions of Section&nbsp;7 of the original Lease, except that Section&nbsp;7.6 of the original Lease is hereby deleted and of no further force or effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e. On or before January&nbsp;4, 2027, Tenant shall cause a Letter of Credit in the amount of $5,201,426.00 to be issued by
JPMorgan Chase Bank in the form attached hereto as Exhibit B and satisfying the conditions of Section&nbsp;7.1 of the original Lease (the &#8220;<B>Unconditional Letter of Credit</B>&#8221;). The Unconditional Letter of Credit shall expressly permit
Landlord to draw the full amount (or any portion thereof) commencing on January&nbsp;4, 2027 for any reason in Landlord&#8217;s sole discretion. Notwithstanding the foregoing, subject to Landlord&#8217;s prior written approval, Tenant may satisfy
all or a portion of the $5,201,426.00 requirement with (i)&nbsp;the Unconditional Letter of Credit and/or (ii)&nbsp;a cash deposit delivered to Landlord on or before January&nbsp;4, 2027, in such combination as Landlord may approve. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f. If Tenant fails to satisfy its obligations under Section&nbsp;2(d) and/or
Section&nbsp;2(e) on or before January&nbsp;4, 2027, then, without limitation of any other rights or remedies of Landlord, such failure shall constitute an immediate Event of Default under the Lease, and no notice of default, notice to cure, or cure
period shall be required, the same being hereby expressly waived by Tenant to the fullest extent permitted by applicable law. Upon the occurrence of such Event of Default, Landlord shall have the right to immediately exercise any and all rights and
remedies available under the Lease, this Amendment and at law or in equity, including, without limitation, the right to terminate the Lease with respect to the Premises and to commence summary process proceedings or any other action or proceedings
to recover possession of the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><U>Remainder Premises; Tenant&#8217;s Share</U></B>. Effective as of May&nbsp;1, 2026, all
references in the Lease to the &#8220;Premises&#8221; shall be considered references to the Remainder Premises, containing a total of 36,882 rentable square feet. Effective as of May&nbsp;1, 2026, Tenant&#8217;s Share of Operating Costs and Taxes is
deemed to be 24.25%, which amounts shall continue to be paid by Tenant in accordance with the applicable provisions of the Lease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.
<B><U>Remainder Premises Term; Landlord Termination Option</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. The Term of the Lease is hereby extended and the
new Expiration Date of the Lease shall be December&nbsp;31, 2036, subject to the terms and conditions set forth below and otherwise as provided in the Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Landlord shall have the right to terminate this Lease at any time during the Term after January&nbsp;1, 2027 (the
&#8220;<B>Landlord Termination Option</B>&#8221;), upon at least nine (9)&nbsp;months prior written notice to Tenant. If Landlord shall elect to terminate the Lease under this Section&nbsp;4(b), (i) the Lease shall terminate on the date set forth in
Landlord&#8217;s notice as though such date was the Expiration Date of the Lease for all purposes, and (ii)&nbsp;Tenant&#8217;s Base Rent shall be abated for the final full calendar month immediately preceding the new Expiration Date set forth in
Landlord&#8217;s notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><U>Base Rent</U></B>. Notwithstanding anything to the contrary contained in the Lease, effective as of
May&nbsp;1, 2026, except for the initial Deferred Base Rent provided in Section&nbsp;6 below, Base Rent shall be payable solely with respect to the Remainder Premises in the following amounts and at the times and in the manner provided in the Lease
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Lease Period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annualized&nbsp;Base&nbsp;Rent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Monthly&nbsp;Base&nbsp;Rent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="border-bottom:1.00pt solid #000000"><B>PSF</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;1, 2026 &#8211; November&nbsp;30, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;2,939,495.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;244,957.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;79.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2026 &#8211; November&nbsp;30, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,027,680.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;252,306.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;82.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2027 &#8211; November&nbsp;30, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,118,510.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;259,875.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;84.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2028 &#8211; November&nbsp;30, 2029</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,212,065.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;267,672.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;87.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2029 &#8211; November&nbsp;30, 2030</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,308,427.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;275,702.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;89.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2030 &#8211; November&nbsp;30, 2031</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,407,680.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;283,973.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;92.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2031 &#8211; November&nbsp;30, 2032</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,509,911.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;292,492.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;95.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2032 &#8211; November&nbsp;30, 2033</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,615,208.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;301,267.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;98.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2033 &#8211; November&nbsp;30, 2034</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,723,664.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;310,305.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;100.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2034 &#8211; November&nbsp;30, 2035</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,835,374.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;319,614.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;103.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2035 &#8211; November&nbsp;30, 2036</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;3,950,436.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;329,203.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;107.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;1, 2036 &#8211; December&nbsp;31, 2036</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;4,068,949.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;339,079.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;110.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><U>Initial Deferred Base Rent</U></B>. Notwithstanding the foregoing Base Rent table, the parties agree
that the Base Rent for the period from May&nbsp;1, 2026 through December&nbsp;31, 2026 shall be deferred and not payable monthly by Tenant during such period. Such deferred amount of Base Rent is included in, and satisfied by the delivery of, the
Unconditional Letter of Credit as provided in Section&nbsp;2(e) above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B><U>New Leasing Activity</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. As additional consideration for Landlord entering into this Amendment, Tenant agrees that, during the Term of this Lease, if
Tenant or any Affiliate of Tenant has a bona fide, board- or executive-approved requirement for additional lab or office space for Tenant&#8217;s own use in the greater Boston market, Tenant shall first present such requirement to Landlord before
pursuing space with any third party. This obligation shall continue until Tenant and/or its Affiliates have entered into binding obligations for an aggregate of 85,000 rentable square feet of space with Landlord or Landlord&#8217;s Affiliates in the
greater Boston market (which, for the avoidance of doubt, shall include the 36,882 rentable square feet under this Lease). Tenant&#8217;s notice (&#8220;<B>Tenant&#8217;s Notice</B>&#8221;) shall describe the general scope and timing of such
requirement. Landlord shall not be required to satisfy Tenant&#8217;s entire space requirement, but any space offered by Landlord must be capable of substantially meeting Tenant&#8217;s requirement as described in Tenant&#8217;s Notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Within thirty (30)&nbsp;days after Landlord receives Tenant&#8217;s Notice, Landlord may, in its discretion, deliver to
Tenant a written response (&#8220;<B>Landlord&#8217;s Response</B>&#8221;) identifying space within Landlord or Landlord&#8217;s Affiliate&#8217;s greater Boston market portfolio that Landlord or Landlord&#8217;s Affiliate can provide and setting
forth the material economic and business terms for such space. If Landlord&#8217;s Response substantially accommodates Tenant&#8217;s stated requirements on market terms, then Tenant shall lease the applicable space from Landlord or Landlord&#8217;s
Affiliate on the terms set forth in Landlord&#8217;s Response. Market terms shall be determined based on commercially reasonable third-party lease comparables for comparable space in comparable submarkets, with appropriate adjustments, as
substantiated by at least one third-party lease comparable provided by each of Landlord and Tenant&#8217;s brokerage representatives. If the parties are unable to agree to the market terms within thirty (30)&nbsp;days after Tenant&#8217;s receipt of
Landlord&#8217;s Response, then each of Landlord&#8217;s and Tenant&#8217;s broker representatives will jointly select a third licensed broker representative from a reputable firm with at least ten (10)&nbsp;consecutive years&#8217; commercial
brokerage experience for office and laboratory space in the area, and such market terms shall be determined in accordance with the &#8220;Baseball Arbitration&#8221; process described in Section&nbsp;1.2 of the original Lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. Tenant and Landlord, or Landlord&#8217;s applicable Affiliate, shall thereafter promptly and in good faith execute an
agreement memorializing such terms, using the form and terms of the original Lease between Landlord and Tenant, modified only as necessary to reflect the deal-specific terms set forth in Landlord&#8217;s Response, but the failure to execute such
document shall not relieve Tenant of its obligation to lease the applicable space from Landlord or Landlord&#8217;s Affiliate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. Notwithstanding the foregoing, this Section shall not apply (i)&nbsp;in connection with a bona fide acquisition of Tenant by
a third party that results in a change of control of Tenant, (ii)&nbsp;in connection with any short-term, swing, temporary, or project-specific space not intended for ongoing operations, provided that any such occupancy shall not exceed six
(6)&nbsp;months in the aggregate (including any extensions, renewals, or successive arrangements for the same space), (iii) in connection with a specialized manufacturing, GMP, vivarium, or other technical space that cannot be accommodated by
Landlord or an Affiliate of Landlord within the greater Boston area; and (iv)&nbsp;from and after the date, if any, that Landlord exercises the Landlord Termination Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e. Neither Tenant nor any Affiliate, nor any other person or entity acting
by, through, under or in concert with Tenant or its Affiliates, shall act in any manner that has the intent or the effect of avoiding, limiting or circumventing Landlord&#8217;s rights or Tenant&#8217;s obligations under this Section, or as a
subterfuge to avoid Landlord&#8217;s right to lease additional space to Tenant or its Affiliate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B><U>Relocation Right of
Landlord</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a. Subject to this Section&nbsp;8, Landlord may relocate Tenant to other space where Landlord or
Landlord&#8217;s Affiliates have authority to enter into leases for space located within a <FONT STYLE="white-space:nowrap">0.75-mile</FONT> radius of the Massachusetts Bay Transportation Authority Alewife Station (the &#8220;<B>Relocation
Space</B>&#8221;), which may include other space within the Building, including the Fifth Floor Premises; provided that the Relocation Space is not less than 25,000 rentable square feet and contains not less than 18,000 rentable square feet of lab
space, with comparable utility access and similar office functionality as the Fourth Floor Premises, including comparable ratios of office to lab space and a comparable number of private offices and conference rooms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b. Landlord shall give Tenant at least nine (9)&nbsp;months&#8217; prior written notice of any such relocation (the
&#8220;<B>Relocation Notice</B>&#8221;). Base Rent and Tenant&#8217;s Share for the Relocation Space will be at fair market value as determined in accordance with Section&nbsp;1.2 of the Original Lease, and shall be based on the square footage of
the Relocation Space; provided that (i)&nbsp;in no event shall Tenant&#8217;s aggregate annual Base Rent or aggregate annual payments of Operating Costs and Taxes for the Relocation Space exceed the corresponding amounts payable for the Remainder
Premises immediately before relocation, even if the Relocation Space is larger, and (ii)&nbsp;if the Relocation Space is smaller than the Remainder Premises, Base Rent and Tenant&#8217;s Share shall be reduced proportionately based on the relative
square footage. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c. Landlord shall, at its sole cost and expense, deliver the Relocation Space in a condition that is
substantially comparable in quality, fit and finishes to the Fourth Floor Premises as of the date of the Relocation Notice, including comparable lab infrastructure, utility access, office space, conference rooms and furnishings. Landlord shall pay
or reimburse Tenant for all reasonable costs of relocation, including moving costs and the costs to prepare the Relocation Space for Tenant&#8217;s use. Landlord shall coordinate the relocation with Tenant and use commercially reasonable efforts to
incorporate recommendations from Tenant into Landlord&#8217;s proposed relocation timeline to minimize disruption to Tenant&#8217;s business operations. Landlord shall be required to make the Relocation Space available for Tenant&#8217;s occupancy
prior to the date Tenant is required to vacate the Remainder Premises. In addition to the rights set forth in Section&nbsp;2.4 of the Lease, upon at least twelve (12)&nbsp;hours&#8217; prior written notice, Landlord may enter the Premises in
connection with relocation efforts, including tours with prospective tenants and their representatives, and Tenant shall permit such access. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d. Tenant and Landlord, or Landlord&#8217;s applicable Affiliate, shall promptly and in good faith execute an agreement
memorializing the relocation, using the form and terms of the original Lease between Tenant and Landlord, modified only as necessary to reflect the deal-specific terms set forth in the Relocation Notice and as determined by this Section&nbsp;8, but
the failure to execute such document shall not relieve Tenant of its obligation to lease the Relocation Space from Landlord or Landlord&#8217;s Affiliate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B><U>Parking Spaces</U></B>. Effective as of May&nbsp;1, 2026, the Parking Spaces
available to Tenant at the Parking Areas of the Property shall be equal to twenty-eight (28)&nbsp;Parking Spaces. In addition, Tenant shall be permitted to use an additional eight (8)&nbsp;Parking Spaces, on a month to month basis, terminable by
Landlord upon thirty (30)&nbsp;days&#8217; written notice. Tenant&#8217;s access to and use of such Parking Spaces shall be subject to and upon all of the terms and conditions of Section&nbsp;1.3(b) of the Lease, provided that in no event shall the
monthly fee for Tenant&#8217;s Parking Spaces be less than $200 per space per month. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B><U>Flagship Subleases</U></B>.
Section&nbsp;13.8 of the Lease shall remain in effect, except that (a)&nbsp;Tenant shall deliver to Landlord at least thirty (30)&nbsp;days&#8217; advance written notice prior to executing a Flagship Sublease, and Tenant shall use its best efforts
to keep Landlord regularly apprised of any potential activity related to a Flagship Sublease, and in any event shall provide Landlord with monthly written status updates on any such activity or interest, once it becomes substantive, (b)&nbsp;Tenant
shall not enter into any Flagship Sublease that would interfere with or impede Landlord&#8217;s termination right, relocation right, or any other rights under this Amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <B><U>Inapplicable Provisions</U></B>. Effective as of May&nbsp;1, 2026 the following provisions of the Lease are hereby deleted and of no
further force or effect: Section&nbsp;1.2 (Extension of Term); Section&nbsp;4.5 and 4.6 (Vivarium); Section&nbsp;12.2 (Signage); and Section&nbsp;26 (Right of First Offer). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <B><U>Shared Building Systems</U></B><B>.</B> Effective as of the Early Termination Date, all tenant systems, lab infrastructure, and
utility distribution equipment that serve, or are capable of serving, both the Remainder Premises and any of the Early Termination Premises, including without limitation supplemental HVAC, lab <FONT STYLE="white-space:nowrap">non-potable</FONT>
water, lab gases, compressed air and vacuum, RODI system, electrical, controls, and IT/telecom (collectively, the &#8220;<B>Shared 4&amp;5 Floor Systems</B>&#8221;), are hereby deemed the property of Landlord, which, for the avoidance of doubt, does
not include the exhaust and backup systems currently and exclusively serving the animal care facility on the Fifth Floor Premises. To the extent (if any) that Tenant holds any right, title, or interest in any Shared 4&amp;5 Floor Systems, Tenant
hereby confirms and, to the extent necessary, conveys the same to Landlord, with such confirmation and conveyance deemed included in the <U>Exhibit A</U> bill of sale; provided, however, Tenant shall continue to remain responsible for operating and
maintaining all Shared 4&amp;5 Floor Systems in a Class&nbsp;A manner, which shall require preventative maintenance contracts for all Shared 4&amp;5 Floor Systems and shall provide Landlord reports upon request. Landlord shall have the sole and
exclusive right, but not the obligation, without Tenant&#8217;s consent, but with written notice to Tenant (a &#8220;<B>Maintenance Notice</B>&#8221;), to operate, modify, relocate, replace, <FONT STYLE="white-space:nowrap">sub-meter,</FONT> and
reallocate the capacity of all or a portion of the Shared 4&amp;5 Floor Systems (including any capacity historically attributable to the Early Termination Premises) to any new or existing tenant of the Building, and to enter the Remainder Premises
at reasonable times and on reasonable notice (or without notice in an emergency) for any such purpose, provided that Landlord shall continue to provide service to the Remainder Premises on a <FONT STYLE="white-space:nowrap">pro-rated</FONT> basis
and at a quality substantially comparable to that available immediately before such Maintenance Notice and shall use commercially reasonable efforts to minimize unreasonable interference with Tenant&#8217;s operations while performing any such
maintenance or other work in the Remainder Premises. Tenant shall not modify nor interfere with any Shared 4&amp;5 Floor Systems or Landlord&#8217;s exercise of its rights under this Section. For the avoidance of doubt, if Landlord enters into a new
lease or leases with occupants other than Tenant, Landlord&#8217;s Maintenance Notice </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall include Landlord&#8217;s assumption of the operations of the Shared 4&amp;5 Floor Systems. At Landlord&#8217;s election, the costs of the Shared 4&amp;5 Floor Systems shall be separately
metered or allocated on a pro rata basis for the applicable tenants utilizing each such system, and Tenant shall pay its pro rata share of such costs as Additional Rent (with corresponding exclusion from Operating Costs for similar services provided
to other tenants in the building). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <B><U>Brokerage</U></B>. Landlord and Tenant each represent and warrant to the other that neither
of them has employed or dealt with any broker, agent or finder in carrying on the negotiations relating to this Amendment to the Lease. Tenant shall indemnify and hold Landlord harmless from and against any claim or claims for brokerage or other
commissions relating to this Amendment asserted by any broker, agent or finder engaged by Tenant or with whom Tenant has dealt. Landlord shall indemnify and hold Tenant harmless from and against any claim or claims for brokerage or other commissions
relating to this Amendment asserted by any broker, agent or finder engaged by Landlord or with whom Landlord has dealt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.
<B><U>Miscellaneous</U></B>. (a)&nbsp;Tenant hereby acknowledges that, as of the date of this Amendment, (i)&nbsp;Landlord has no undischarged obligations under the Lease to perform any work or improvements to the Premises, or, to Tenant&#8217;s
actual knowledge, otherwise (other than any obligations that first arise or accrue following the date hereof) ; (ii) there are no current offsets or defenses that Tenant has against the full enforcement of the Lease by Landlord; and
(iii)&nbsp;Tenant has not assigned transferred or hypothecated the Lease or any interest therein or subleased all or any portion of the Premises, (b)&nbsp;Landlord hereby acknowledges that as of the date of this Amendment, and to Landlord&#8217;s
actual knowledge, (i)&nbsp;neither Landlord nor Tenant is in default under the Lease in any material respect; (ii)&nbsp;there are no current offsets or defenses that Landlord has against the full enforcement of the Lease by Tenant; provided that the
foregoing shall not limit any rights, offsets or defenses of Landlord arising from Tenant&#8217;s obligations under this Amendment that remain unsatisfied, and (iii)&nbsp;Tenant has not assigned, transferred or hypothecated the Lease or any interest
therein or subleased all or any portion of the Premises. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <B><U>Ratification</U></B>. Except as expressly modified by this Amendment,
the Lease is and shall remain in full force and effect, and as further modified by this Amendment, is expressly ratified and confirmed by the parties hereto. This Amendment shall be binding upon and inure to the benefit of the parties hereto and
their respective successors and assigns, subject to the provisions of the Lease regarding assignment and subletting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <B><U>Governing
Law; Interpretation and Partial Invalidity</U></B>. This Amendment shall be governed and construed in accordance with the laws of the Commonwealth of Massachusetts. If any term of this Amendment, or the application thereof to any person or
circumstances, shall to any extent be invalid or unenforceable, the remainder of this Amendment, or the application of such term to persons or circumstances other than those as to which it is invalid or unenforceable, shall not be affected thereby,
and each term of this Amendment shall be valid and enforceable to the fullest extent permitted by law. The titles for the paragraphs are for convenience only and not to be considered in construing this Amendment. This Amendment contains all of the
agreements of the parties with respect to the subject matter hereof, and supersedes all prior dealings between them with respect to such subject matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <B><U>Counterparts; Signatures</U></B>. This Amendment may be executed in counterparts,
each of which shall be deemed an original, but such counterparts, when taken together, shall constitute one agreement. Signatures of the parties transmitted by electronic mail PDF format or using electronic signature technology (e.g., via DocuSign
or similar electronic signature technology), and such signed electronic record shall be valid and deemed to constitute originals and may be relied upon, for all purposes, as binding the transmitting party hereto. The parties intend to be bound by
the signatures transmitted by electronic mail PDF format, are aware that the other party will rely on such signature, and hereby waive any defenses to the enforcement of the terms of this Amendment based on the form of signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signatures Appear on Following Page] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment as of the day and year
first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B><U>LANDLORD</U>:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B><U>TENANT</U>:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">101 CPD LLC, <BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">SERES THERAPEUTICS, INC.,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">a Delaware limited liability company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">a Delaware corporation</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><U>/s/ Scott R. Bohn&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>/s/ Richard N. Kender&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P>
<P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Scott R. Bohn </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Richard N. Kender</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Its: Chief Development Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Its: Executive Chair and Interim Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d156701dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;99.1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g156701g69i94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SERES THERAPEUTICS ANNOUNCES TWO TRANSACTIONS TO STRENGTHEN </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEET, REDUCE OPERATING COSTS AND EXTEND PROJECTED </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OPERATING CASH RUNWAY WELL INTO THE FIRST QUARTER OF 2027 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Agreement with Nestl&eacute; Health Science provides $25&nbsp;million payable to Seres in 2026 as a
<FONT STYLE="white-space:nowrap">buy-out</FONT> of </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>potential future VOWST<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP>
net sales-based milestones </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Restructured lease materially reduces ongoing annual facility cash costs and long-term lease liability
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Clinical data from investigator-sponsored <FONT STYLE="white-space:nowrap">SER-155</FONT> study in immune checkpoint
inhibitor-related enterocolitis expected later this month </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass.- June&nbsp;5, 2026 &#8212; Seres Therapeutics, Inc. (Nasdaq: MCRB),
(&#8220;Seres&#8221; or the &#8220;Company&#8221;), a leading live biotherapeutics company, today announced two transactions to strengthen its balance sheet and extend its expected operating cash runway well into the first quarter of 2027. Seres
entered into an amendment to the prior asset purchase agreement whereby Nestl&eacute; Health Science will now pay Seres $25&nbsp;million (in two equal installments in July and October 2026) to buy out potential future VOWST<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> net sales-based milestones, and a restructured lease agreement for one of Seres&#8217; locations which materially reduces the Company&#8217;s leased space and ongoing annual facility cash costs
and long-term lease obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seres previously developed VOWST, the first orally administered microbiome-based therapeutic approved by the U.S. Food
and Drug Administration for the prevention of recurrence of <I>Clostridioides difficile</I> infection in adults following antibacterial treatment for recurrent CDI. Seres sold the VOWST business to Nestl&eacute; Health Science in 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;We have taken meaningful actions to strengthen our balance sheet and extend our cash runway well into the first quarter of 2027,&#8221; said Richard
Kender, Executive Chair and Interim Chief Executive Officer of Seres. &#8220;The Company intends to continue to exercise rigorous financial discipline while advancing its live biotherapeutic programs in inflammatory and immune diseases and pursuing
partnerships and other sources of capital to support continued pipeline development, including Phase <FONT STYLE="white-space:nowrap">2-ready</FONT> <FONT STYLE="white-space:nowrap">SER-155</FONT> in allo-HSCT. We look forward to the clinical
readout expected later this month from the investigator-sponsored study of <FONT STYLE="white-space:nowrap">SER-155</FONT> in immune checkpoint inhibitor-related enterocolitis being conducted at Memorial Sloan Kettering Cancer Center, a long-term
collaborator with Seres.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;These transactions will improve our financial flexibility, and the lease restructure marks progress in our goal to
reduce our leased space to align with our focused corporate strategy,&#8221; said Marella Thorell, Chief Financial Officer of Seres. &#8220;We are pleased with these outcomes, which will provide near-term capital from the Nestl&eacute; agreement and
significantly reduce our ongoing annual facility-related cash spending via the restructured lease. Importantly, while reducing fixed costs and preserving capital, we are maintaining the operational infrastructure needed to support our pipeline as we
pursue additional sources of funding and strategic opportunities.&#8221; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2026, Seres had $29.8&nbsp;million in cash and cash equivalents. Based on the
transactions described herein and current operating plans, Seres expects to fund operations well into the first quarter of 2027. This projection excludes proceeds from any potential future partnerships or other sources of capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional details regarding the Nestl&eacute; Health Science asset purchase agreement amendment and the lease amendment are included in the Company&#8217;s
Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> which will be filed with the Securities and Exchange Commission today. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment to
Asset Purchase Agreement with Nestl&eacute; Health Science </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seres sold its interest in the VOWST business to Nestl&eacute; Health Science in 2024.
Seres has entered into an amendment to the asset purchase agreement whereby Nestl&eacute; Health Science will pay Seres an aggregate of $25&nbsp;million, in two installments of $12.5&nbsp;million each on July&nbsp;1, 2026, and October&nbsp;1, 2026,
to <FONT STYLE="white-space:nowrap">buy-out</FONT> the potential future milestones due to Seres if and upon the achievement of certain VOWST net sales targets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lease Restructuring </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seres has amended its lease with its
landlord for the Company&#8217;s facility at 101 CambridgePark Drive in Cambridge, Massachusetts, reducing its leased space, rental rate and facility operating expenses. Under the amended arrangement, Seres will lease the retained space for a <FONT
STYLE="white-space:nowrap">10-year</FONT> term at market-adjusted annual rent and a lower percentage of shared operating expenses for the building as of May&nbsp;1, 2026, in exchange for the landlord drawing the existing letter of credit, Seres
payment of a termination fee and the establishment of a new letter of credit.<B> </B>The restructured lease is expected to materially reduce the Company&#8217;s ongoing annual facility-related costs and long-term obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Seres Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seres Therapeutics, Inc.
(Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics, with a focus on inflammatory and immune&nbsp;diseases. The Company led the development and FDA approval of VOWST<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>, the first orally administered microbiome therapeutic, which was&nbsp;subsequently&nbsp;divested to Nestl&eacute; Health Science. <FONT STYLE="white-space:nowrap">SER-155,</FONT> which has
received Breakthrough Therapy and Fast Track designations, is&nbsp;being advanced&nbsp;for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT), and&nbsp;is&nbsp;Phase 2 ready,&nbsp;pending receipt of funding. An
investigator-sponsored trial of <FONT STYLE="white-space:nowrap">SER-155</FONT> is ongoing in immune checkpoint inhibitor&#8211;related enterocolitis (irEC) to further evaluate the potential breadth of the Company&#8217;s live biotherapeutic <FONT
STYLE="white-space:nowrap">platform.&nbsp;SER-603,</FONT> in development&nbsp;for inflammatory bowel disease, is designed to modulate the gastrointestinal microbiome and support mucosal barrier integrity by targeting inflammatory bacteria and
associated metabolites.&nbsp;For more information, please visit <U>www.serestherapeutics.com</U>.<B></B> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in
this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: anticipated payments under the amendment to the asset purchase agreement with Nestl&eacute; Health
Science; the expected effects and benefits of the restructured lease, including reduced ongoing annual facility-related cash costs and long-term lease obligations; the Company&#8217;s expected operating cash runway; the timing and results of
clinical studies and data readouts, including the investigator-sponsored study of <FONT STYLE="white-space:nowrap">SER-155</FONT> in immune checkpoint inhibitor-related enterocolitis; the advancement of
<FONT STYLE="white-space:nowrap">SER-155</FONT> and other pipeline programs; the Company&#8217;s ability to support its pipeline and to enter into partnerships or obtain other sources of capital; and the anticipated timing of any of the foregoing.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on management&#8217;s current expectations. These statements are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, the following: (1)&nbsp;our need for additional funding; (2)&nbsp;our ability to continue as a going concern; (3)&nbsp;we have incurred significant losses, are not currently profitable and
may never become profitable; (4)&nbsp;our cost reduction actions may not achieve their intended benefits, including an extended cash runway; (5)&nbsp;our limited operating history; (6)&nbsp;we may not be able to realize the anticipated benefits of
the VOWST sale, and may face new challenges as a smaller, less diversified company; (7)&nbsp;we have in the past and may in the future receive notice of the failure to satisfy a continued listing rule from The&nbsp;Nasdaq Stock Market LLC;
(8)&nbsp;our novel approach to therapeutic intervention; (9)&nbsp;our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (10)&nbsp;our ability to achieve market acceptance necessary for commercial
success; (11)&nbsp;the competition we will face; (12)&nbsp;our ability to protect our intellectual property; (13)&nbsp;impact of our recent management transitions and appointments and our ability, to retain key personnel; and (14)&nbsp;disruptions
at the FDA or other government agencies. These and other important factors discussed under the caption &#8220;Risk Factors&#8221; in our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended
March&nbsp;31, 2026 filed with the Securities and Exchange Commission (SEC) on&nbsp;May 5, 2026, as well as our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking statements represent management&#8217;s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any
obligation to do so, even if subsequent events cause our views to change except as required by law. These forward-looking statements should not be relied upon as representing our&nbsp;views as of any date subsequent to the date of this press
release. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor and Media Contact:</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>IR@serestherapeutics.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carlo Tanzi, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kendall Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ctanzi@kendallir.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mcrb-20260602.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 6/5/2026 1:35:04 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:mcrb="http://serestherapeutics.com/20260602"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://serestherapeutics.com/20260602"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" namespace="http://xbrl.sec.gov/stpr/2025" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mcrb-20260602_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mcrb-20260602_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mcrb-20260602_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 6/5/2026 1:35:04 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mcrb-20260602_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2606 Build:20260317.3 -->
<!-- Creation date: 6/5/2026 1:35:04 PM Eastern Time -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="mcrb-20260602.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g156701g69i94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g156701g69i94.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MXQ?LM:UX8TSQS?)IUEK6@ZB-1@T^0@L7N,91455+,6=2 I(#=*^\A0!\=_\
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MP'X0\0ZO?ZQK_P 0/%]W=KJGA^QBCDNKO,B[)1NY@21WP%VDL%.,XXX7XO?
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7W)$_F))(",Y#@'"E0=JY!  KKZ /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 02, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001609809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  02,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SERES THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-4326290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">101 Cambridgepark Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">945-9626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MCRB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d156701d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d156701d8k.htm">d156701d8k.htm</File>
    <File>mcrb-20260602.xsd</File>
    <File>mcrb-20260602_lab.xml</File>
    <File>mcrb-20260602_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d156701d8k.htm": {
   "nsprefix": "mcrb",
   "nsuri": "http://serestherapeutics.com/20260602",
   "dts": {
    "inline": {
     "local": [
      "d156701d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "mcrb-20260602.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mcrb-20260602_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mcrb-20260602_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2026-06-02_to_2026-06-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d156701d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2026-06-02_to_2026-06-02",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d156701d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://serestherapeutics.com//20260602/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-26-258366-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-258366-xbrl.zip
M4$L#!!0    ( *A8Q5S]>?!;*18  (*&   .    9#$U-C<P,60X:RYH=&WM
M7>ESXL:V_^Z_HHO,)/8K-K'8!GNXY6!/PHVW,LZ[J?<EU4@-=$:HE6[)F/O7
MOW.Z)2&Q&(S!GIDXE<0@]7+Z;'U^IQ=.__4X<LD#DXH+[]-/5K'\$V&>+1SN
M#3[]=-9M=SH__:NU=SH,H!@4]5338?Q3;A@$?K-4>NQ)MZB871R(AQ*\*%7*
ME7HN*ABJ0C#QF4I*]ZGJ%84<E.(WF>*>\+QPE!0>C\=%W3Q6< )9PAHE*%2
M4DQR.Z[WZ'+O2Z;:N*HK68U&HZ3?QD7G2B8=5,KE:@E?]ZAB<?&1+7M)<<4D
M4\&02>JS,."V*MIBA ,X+!^6*PDQBB\B!9JW2G]<77;M(1O1 O=40#T[Z2@,
MY%*R&B5X&Q?D2M0JUM$38XA*)!4>EY6UH*P'(V9__'QW.2T>+"X_+5H*)/54
M7\@1#4!GL*5ZH5PI5 Y3C11 )S(-Q3JRJIWC0M5*> F=\Z>&.L-%?.O,Z&94
M^+!D7L9%E0SFM1(>9A12!;Y<K.GX)EUTN?:AW>30?AAUX$_  Y>UC@N_G9;,
MQ[W3$0LHP>H%]G?('S[EVL(+F!<4[D'?<\0VWS[E O88E'1S):A5,@T20DY[
MPIFT3AW^0%0P<=FGG,.5[]()&A3+M<@I?VQB:2:CS]QQF&<^0Y%K8TW$HR.L
MRWCS;,0\!_X+/KMT$%'P&-RQ/KP.I9;6GZCWA3+\6_DS$*EO.<*=3SG^^ !R
MK.5:?>HJ=EK*]#37,];X51/U)W3_YX4'K)FTH7])W8[GL,??V"27HF])@>?1
MV2J#21Z6&\?EQCQ]I1DV2=8'ZP=54_ =O413:4.&OG;IA'1/Z/8^Y10?^6[R
M;"AQD.B>"K$#*CXJ)WY-I2T%:L+J3DK1:#,CU-^5"*7YJNVP&;%72VL-]L;5
MF!96\I4[^*#/F22:A6RAEVAW?LL*:+8R4KVP?1\D*)SD*S@(&9S3@+6FM,4U
MI^^FM#I+RL9ODFZ3?DH9[B3<G'*OE#:_$I@I_$D9*]8J4)</O*8-8V$REWT_
MYDXP;!X7Z]P[295U63\X&5$YX%X!/S<)#0,1/Y%\,(P>S32'WK<P9/H]3/9^
MTD@@_&;J:T\$@1CI)STA@?CXB>4_$B5<[I ?ROJ?7.O''T!.)PO&ENZLNKJS
MRO,[\^.N4@W7H!DR/PS2!Q$5%/\O:UK'R?<^'7%WTKSG(Z;(-1N3.S&BWHE^
M-S:4]X3KG"P0T^_7G?N+<]*]/[N_Z)Z6_"7DE%^)G.Y%^_>[SGWGHDO.KL_)
MQ1_M7\^N?[D@[9NKJTZWV[FY?A&-E6W0^)^S[J^=ZU_N;Z[SY+S8+I)*N5YK
MS- UT^DJ_9RJA/\\RTIKY^%&VEDL0[&L@IX8>ZU8'^?'OZ:]IC7\*3TW(GD%
MS?I\<W=%3I5/O<0I#7G "O#$9C!QCB$DSK66AA/GP@XQFDC%,QM$$Q!KF;@I
M.U>?EI"NUKL*[4R%MF+XX)KN+J[OR=W%[<W=_=L[HMM0JI!Z 0D$Z3(;E9!8
M52(DL>K[SL';$RCZ!+ FTA9*'G"H?_%H#ZDW8.3,#@B\MAK5VG(Z7TVR&!8A
M.7?,%S(@^_%W1B$L L!,V .4)%*_9LY!<SGNB!W%K8ZM+DS(]6R/81 E>HV@
MZ4 #(Z@^=.AD A0Q+^U1#G.M?X<>(Y4\P0;F7<N[3]F-3ZG4MJ%YRQ7) ,0[
M-N *DPS!-;QYP<QSA,'5'<15][]>W)W=7OQ^WVEW\Z1SW2XN@(XO\!SE;;!E
M_^*1@H= ;AB[C+E J")=G]D(H!S"/=()%&D/ 00Q.>OQWI7]"65_"7/V3@/:
M<QFQF>MB_(1IUEPYI[_[U''B[U%7T6!MX;K45ZP9?WA:35(ZA0&@88=5+G^,
MF1?UW"Q'U#;+,58$^J3^OY,%H-7:1\P5I%\\,!EPF[H1?\V 9PM%M2OKU8Y)
MG2N=;N:T%)$HX[<^';!"3S+Z!3.KW&%-^B! '];FDJ7%]!1](-U%QI:)BF>M
M\XF8V'BHCF<+"?.B=D7= ":KM@B]0$[:PGG1Q(?I5\QO!,R7X@&[S<Y\QS!O
M,Y>.849<&E 'SCKB3G1[1?$-^;<QZ# ,_LQ=!N]ZT-7F[K^!J2BK4#VJ'=:7
M<NL[8MH]?>Q$B39;<^FE'*R6<ZW*4:$&$5>E45Z#A3NP\.,-#7S3N7PKP'M?
M^P1$)0(7GLA?@ 64PS5<>5:@8>V .(@M>-I_Z1#BE2S@;:72%J,15^IK$ (Z
M.&+L\Y_#_\Y=EUR,?%=,F'QS"61=);D6Q:D@M!^#_V'$]ZT&D!J4;"."K)>W
M$@/6CK^O&/#,<213*OIS"7C(>L%,:^5:5MDB;3KJ2>X,F$_E%W(N^<,KQGEO
M)9Y(?78EH39\O)'W8NR]0#Z57"N1S:Q$\JL2&A$A.BBXD;<0V7.]^V%C:JJY
MUM79*RG&CJ5S*P#NN/_'_8V@TY0E-0CV*U9M>93Z=86G*WBW'W$'$T&^!&WA
M/G4)>V1V&(!/@,<P<3%U\%7AEWV0(D$Q'LPQ?<%<^LR<]U92;-.<VH\_'%>L
MHQ-% N8R?R@\1CP=C>4Q.'9#G(X)H&P*&@E:L=S"T;N<0;D7JF\=V'=H'1W,
MYR4W!H67 @1ZBT-[,0X\S+4:M7JA<;@HV;YH'>\MA'LM G+F^R[H,:C:2_*Y
MVXEV/PL)+"+7.I\K2?0U,FQ0LS[F<+T!<T@7IP-R2540K<:\9W5WMRRZ2M=@
MHA\R^XM>Q:.^+P7X7P3S/?%(>LP58Y0<OD2!KC9/O?2M383TN8M>A2MP,0'S
M')!\((CBH] -J,=$J-P)46"5JC_1/4051 \X9E!*M+HHIVL#(;0C"?4F\;L^
M  4QQGJ80N2(=E5SJ3X=;@ICM@I3YK#)%+?, Z09 +76A)Y;B$@^GCP][Z%6
M/N%@_R-Y '+$K$+H13A2O3C[VQ/"[5&080 :EW;"1RB'QE&M=C+O@Y\WGYMQ
MI?2!9%6 O-A?SW46\0J8DV86\5/+^7<AJ%6M4H]4>F85'1?/]ZTCTOY\1RK5
M<A$*/@>OO^OYYGK>!6]N@Q2\P14X0O"&[NZ4_/A;5O(IHZ!IPZEY#5\Y8U@U
M6K J\:0Q-8;,/I+8%%:V5JF5BZ;%@U2H]FXU.[>:6\EP9L"MV7H3'4[X\J;?
MWR 07]MZ&M^R]:Q49>!HP4ZQ-#:157/*&A;G%"K[O8/MVIQI\]WJWM+J.DJ%
M3+Z&[=7*[[:WD>U56:&V;V_7]J(VU[:]K4/(5.!JL!J3@/;\^<VKQHHM]!0Q
M@(/A+L=K7_^ZT_O&I<WRQFLD4I:,8,X*7K3RNXNUUGL\,FDV%]M#8KM4J:TL
M>F_,LZ^.09*B(9[V9*G5G8R@V+[:SKZ [X9%U]&^6*U"+)H;-,.$1\ &X.G4
MU68]_M>RWKP48)O98F)5>MI2-L_4UZQ<"^,?@7.DL+_DB4\E>:!NR,B',@C?
M(CZ>X!PNW$#X.HM(R[@0V8!1_Q>PH))K7;7O?O[:AA<+.0YK-MK;/AN-HAW,
M[1*M5<&A0"!Q395#_R9=5 1R1>47%I#+R_9"QKQ:9-3Q'(P6&>E-B*T3[2/<
MZC >,KU3;B:[S16!< \B3NQT0 92C(,A!IT^9KRI(@[K<\_LBC?YPW*=S!_!
MF9Z\J9)]E._1B4DBQJ6A'Y"*CQOJ<:UFS="UTBLD>9KUSOTDO:\7Q\YUD**S
MN-LEMUSK8@G75ZSKQ]5^T;7:IM+N8%?M"=BU6_YT^D_H)BXC+U1T/K>",P0U
M9B[  5!C3VAP$"JF2P'#HG4BO'*#ZR4@<X =&:3[<B?8^9A#UR@<#^B#-Y(]
M< 7UP#BH9V,>DMHV;E''PGCYAD.EH\P*D?,D,JGNTP29I#6Z2!*V+X,JZQQ2
M7[I4^5V==\^L7.[M+59*-IK327R4BE=Z#*0.\8H[IA.5,V>6]DZ'26@#6$W(
MY@\-_<])/![_,8W';)=1B7/=4".>O17+P]N]T6!O-E7U\\W=^<5=H7US>7EV
MV[UHQA^^A5259:V9JWIZUTPG8"/<C5*V3D#/K>*Z6WI>/6GT5)!N>K_ (S"X
MN"T()?%:$3G'*9KK;4MG \ET^JA(GI.3.=S!#I)%<M&?FSR ,=FY5G*;#KJ_
M,Z4@>KH-)7A E1K(RNTO6Z ]U[KQ"!YX-2XE.O6:!T<MH=A]ZF:K/.EX=I'L
MH[-&G:J43Z()6'^S3@Z(MFL=,(&4ID.\%L7(X6=JG]V>30LE;4!-G:A:PI,\
MP>.[#H9GR+EP$*K -%[7I$,41''N@3G*['F@(S/+]7#; PW 1&5 (:*[9$&
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MHQ=>Y_7% ,3^2U7LI>L%__N-.V=_//%_(R(_61SDTKW#@AV1=C>=7 T&5V]
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M O=E(#X>": M&+ "O'=Z*27$'0,D)7"O;,I; %F4AQ,UFL<P(1"4^C*+8"T
MLH\R"R=,OST22;W>2H[]?5CENY:A:X2,Y04CE>,R<<'(E@Q3@MU8D8NG!(_"
MC_ 3$"EO!7<./*Y0CI[$701(!IQR!BQ T#A*--%4L+[&/]61DA%1"I!\)/B
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MQLE":9BEGQ4U1LJ4EJX2Q7U.&%.R73(4APR.U-1?3#5">@"^NY\QU!@@]Z'
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M8 \^ZKN%3X$;T/H-83+)X5\ (VJ]E:GF$VD(*<_1R5A9; BP';FRJ1Y[]JT
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M<V>OCH%*2C>ST.,4NKM?^C'M5Q\BBZ9MX]#S1#-05]DML]Z:AZW&F%JT 59
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MANSN'/ (_G/[0!@23@G_JFOFB8R7_N6+AI#D)B'Y5:1OE!AKDU56@E_Q]PW
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M9QQ7\5//52S@GY6NRPT;B:#=S1E^*75$;PD/(7LZ65)/7MXZB#Q=8W,(S,&
MB'<KNUX>19=!@W?&S),X/>T>H,U_6W5,[M>Y=2:&UJ7VLLE@"MM?[8%4[RH#
MD36T"R\20]N0D9B@P'DNN8>[F%+D/V[&4B]^G!,ZD&A\7FD-?P^?#35RHT)Z
MV&[O; Z+PL$<G8:?@4HRWDH,'::I1+] H09KS.EV"=UT2/. 7M&L15CR50@8
M#-T&^_'"\]]D=_KN@:#$5C/E12/UP!4<EN$%'#0CZ[>+V 2Z2%<0.I41K5=!
M;]<3:Q<_S  FG)P]5ON;/;(X]&>/YNQVK98$<:F)8^53VG:[B%$T:S9/>%*T
M2AG[$?$CY9G:%#:WL>-.T+0'6I6IXC$8I_LX.>/FJBA$5F7E^1/] 5*#^.B^
M+XZ,_0V$7]U9(9#G:\^MVCO-7XN"HF O_RQG@QJTH>(%(%*O;3A?_0O'6]M#
M:MM-["8Z0ZSNE8<5_B24J-:\4*AEB=)[*_6Z#;@85>@N\ZUG/;*G2V75Y.;O
M,ACB/Q$,@0.L95&1/)"<"+]##S-WVPIB2)8HIQ#>CQ08D($N)*SYYZK\!<S0
M'E-/,3,%YT^%-BWXF:\^>%!6%"$D;)[PF*=V I=-.0'Y.K6"DGQ#@OPPDIH3
M?[VV*MU9G\!)I&*ZCDB'.ROVC1]1#U:6(#=:+1Q8.?NK6\(1$M#2$;MU:H_D
MHHB-1[;L^S"??@@:E3]5DA7-<HF9^T,NM[Q3)W.H3C7E?GV3=5_+Q.UY-7^'
M\]<^]R+&W0 \4Z&6"!2TL4&V_SV:^,.KH_[@'QN)&D%,S;/?CY<V,F(DXW_K
MAKB<M8X?/1_X)LP)7<$$$HA2\P/JSSA%/.]?>CE"WP Y_W'M-J"MU_)#%!CL
M?W'\.Q[RWS;\/U!+ P04    " "H6,5<7]0AP&X#  "E#   $0   &UC<F(M
M,C R-C V,#(N>'-DO5;=;]LV$'\OT/_AJJ<-F$3+7EQ$B%.T2P,$2+/"38>]
M%;1TMHE2I$922?S?[TA9MB(GKI,4]8M)WOWN^T,G[^Y*"3=HK-!J$J7)( )4
MN2Z$6DRBVL;<YD)$[TY?OSIY$\=P=GYQ!3$LG:MLQMCM[6U2S(6R6M:.)-@D
MUR6#.&[Y_[K^"O\TTC.8HD1N$8;CP1@^U$(6V7! EU'Z-AEU00:YEP8%=YC!
MF!TQSP=I-CK*!G_"YT_PD5N'1L&U*+&+U-7*B,72P6_Y[Q! 9UHIE!)7<"X4
M5[G@$KZTYOX!%RI/X+V4,/4P2S9:-#=8)&NI=[;(;+[$DK]^!4#!4C93)+(N
M)Y&/PCH(=S,C$VT6K'"&N56%C)ABXD(C\J@#_3%N!T-9\!2[ <ZYG0502_'A
M.>H@RMS,-MSD#UJW1,,K)*_S)D<A\./!L(,J4&Q P2Z+>;+0-XP(?0V>+A[V
M9#@8C!B5A*-@8P<BA?J^!^'),ZJ.KI(=R.TH -+CXV,6J#V3"G??@[7T(]80
M.]S6N-UXTF/?4>LJ\W!4/&7+S9TS8E8[/->F/,,YKR4IJ-5_-9=B+K (7-0
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M-7C-L0_8S]GAR*UEC^/6KVW6VEYF_69>OW2;OGEJ1@]=_P=02P,$%     @
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M\@]02P$"% ,4    " "H6,5<_7GP6RD6  ""A@  #@              @ $
M    9#$U-C<P,60X:RYH=&U02P$"% ,4    " "H6,5<$KB3'F@2  "25
M$0              @ %5%@  9#$U-C<P,61E>#$P,2YH=&U02P$"% ,4
M" "H6,5<)C@ZV$,I  "7QP  $0              @ 'L*   9#$U-C<P,61E
M>#$P,BYH=&U02P$"% ,4    " "H6,5<P"TZKMP1  !T.   $0
M    @ %>4@  9#$U-C<P,61E>#DY,2YH=&U02P$"% ,4    " "H6,5<7]0A
MP&X#  "E#   $0              @ %I9   ;6-R8BTR,#(V,#8P,BYX<V10
M2P$"% ,4    " "H6,5<E11[WUL&  "[0P  %0              @ $&:
M;6-R8BTR,#(V,#8P,E]L86(N>&UL4$L! A0#%     @ J%C%7&(;%DNX!
M@RH  !4              ( !E&X  &UC<F(M,C R-C V,#)?<')E+GAM;%!+
4!08     !P ' +X!  !_<P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d156701d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mcrb-20260602.xsd" xlink:type="simple"/>
    <context id="duration_2026-06-02_to_2026-06-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001609809</identifier>
        </entity>
        <period>
            <startDate>2026-06-02</startDate>
            <endDate>2026-06-02</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-314">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2026-06-02_to_2026-06-02"
      id="Hidden_dei_EntityCentralIndexKey">0001609809</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-325">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-326">2026-06-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-327">SERES THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-328">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-329">001-37465</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-330">27-4326290</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-331">101 Cambridgepark Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-332">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-333">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-334">02140</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-335">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-336">945-9626</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-337">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-338">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-339">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-340">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-341">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-342">MCRB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-343">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2026-06-02_to_2026-06-02" id="ixv-344">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
